- Home
- IIIV vs RCKT Comparison
IIIV vs RCKT Comparison
Compare IIIV & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IIIV | RCKT |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.0M | 394.2M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IIIV | RCKT |
|---|---|---|
| Price | $14.73 | $3.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $33.20 | $29.73 |
| AVG Volume (30 Days) | 445.2K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | 0.24 | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | $64.28 |
| P/E Ratio | $61.54 | ★ $5.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $2.53 |
| 52 Week High | $33.97 | $5.45 |
Technical Indicators
Market Signals| Indicator | IIIV | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 45.31 |
| Support Level | $15.59 | $3.36 |
| Resistance Level | $17.12 | $3.65 |
| Average True Range (ATR) | 0.66 | 0.20 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 28.29 | 24.33 |
Price Performance
Historical ComparisonAbout IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.